Campbell David Alan 4
4 · Janux Therapeutics, Inc. · Filed Oct 30, 2024
Insider Transaction Report
Form 4
Campbell David Alan
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-10-28$53.22/sh−13,897$739,650→ 293,157 total - Sale
Common Stock
2024-10-28$53.94/sh−11,103$598,909→ 282,054 total
Footnotes (3)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.
- [F2]The weighted average sale price for the transaction reported was $53.2237 and the range of prices were between $52.5801 and $53.575. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $53.9412 and the range of prices were between $53.58 and $54.445. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.